XML 30 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Segment Information (Tables)
 9 Months Ended
Jan. 31, 2014
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
The following tables summarize, for the periods indicated, operating results by business segment (in thousands):
 
 
 
Personalized
 
Translational
 
 
 
 
 
 
 
 
 
Oncology
 
Oncology
 
Unallocated
 
 
 
 
 
 
Solutions
 
Solutions
 
Corporate
 
 
 
 
Three Months Ended January 31, 2014
 
(POS)
 
(TOS)
 
Overhead
 
Consolidated
 
Net revenue
 
$
590
 
$
3,100
 
$
-
 
$
3,690
 
Direct cost of services
 
 
(608)
 
 
(1,007)
 
 
-
 
 
(1,615)
 
Sales and marketing costs
 
 
(405)
 
 
(352)
 
 
-
 
 
(757)
 
Other operating expenses
 
 
-
 
 
(531)
 
 
(1,254)
 
 
(1,785)
 
Stock- based compensation expense (1)
 
 
-
 
 
 
 
 
(941)
 
 
(941)
 
 
 
Segment profit (loss)
 
$
(423)
 
$
1,210
 
$
(2,195)
 
$
(1,408)
 
 
 
 
Personalized
 
Translational
 
 
 
 
 
 
 
 
Oncology
 
Oncology
 
Unallocated
 
 
 
 
 
 
Solutions
 
Solutions
 
corporate
 
 
 
 
Three Months Ended January 31, 2013
 
(POS)
 
(TOS)
 
Overhead
 
Consolidated
 
Net revenue
 
$
473
 
$
2,444
 
$
-
 
$
2,917
 
Direct cost of services
 
 
(661)
 
 
(561)
 
 
-
 
 
(1,222)
 
Sales and marketing costs
 
 
(361)
 
 
(220)
 
 
-
 
 
(581)
 
Other operating expenses
 
 
-
 
 
(627)
 
 
(637)
 
 
(1,264)
 
Stock- based compensation expense (1)
 
 
-
 
 
-
 
 
(570)
 
 
(570)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(549)
 
$
1,036
 
$
(1,207)
 
$
(720)
 
 
 
 
Personalized
 
Translational
 
 
 
 
 
 
 
 
 
Oncology
 
Oncology
 
Unallocated
 
 
 
 
 
 
Solutions
 
Solutions
 
Corporate
 
 
 
 
Nine Months Ended January 31, 2014
 
(POS)
 
(TOS)
 
Overhead
 
Consolidated
 
Net revenue
 
$
1,834
 
$
7,258
 
$
-
 
$
9,092
 
Direct cost of services
 
 
(2,078)
 
 
(2,572)
 
 
-
 
 
(4,650)
 
Sales and marketing costs
 
 
(1,159)
 
 
(812)
 
 
-
 
 
(1,971)
 
Other operating expenses
 
 
-
 
 
(1,595)
 
 
(2,790)
 
 
(4,385)
 
Stock- based compensation expense (1)
 
 
-
 
 
-
 
 
(1,968)
 
 
(1,968)
 
 
 
Segment profit (loss)
 
$
(1,403)
 
$
2,279
 
$
(4,758)
 
$
(3,882)
 
 
 
 
Personalized
 
Translational
 
 
 
 
 
 
 
 
 
Oncology
 
Oncology
 
Unallocated
 
 
 
 
 
 
Solutions
 
Solutions
 
Corporate
 
 
 
 
Nine Months Ended January 31, 2013
 
(POS)
 
(TOS)
 
Overhead
 
Consolidated
 
Net revenue
 
$
1,850
 
$
4,631
 
$
-
 
$
6,481
 
Direct cost of services
 
 
(2,030)
 
 
(1,740)
 
 
-
 
 
(3,770)
 
Sales and marketing costs
 
 
(495)
 
 
(636)
 
 
-
 
 
(1,131)
 
Other operating expenses
 
 
-
 
 
(1,463)
 
 
(2,418)
 
 
(3,881)
 
Stock- based compensation expense (1)
 
 
-
 
 
-
 
 
(1,934)
 
 
(1,934)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(675)
 
$
792
 
$
(4,352)
 
$
(4,235)
 
 
(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.